Week in Review 43/16

Welcome and thanks for reading! In this review, I will gather together important and interesting news and events over the last week related to my portfolio holdings. In my week review, I put also together some interesting articles from other websites that caught my attention during the past week.

Dividend Increase – AbbVie Inc. (ABBV)

Today, October 28 AbbVie Inc. announced a quarterly dividend increase of from $ 0.57 to $ 0.64 per share that’s payable February 15, 2017 to holders of record January 13, 2017. This represents a 12.3% increase to regular quarterly dividends. With current price $ 61.46 (yesterday's close), this raise brings their dividend yield to 4.17%. 

Since I own 30 shares this will increase my yearly net dividends by $ 6.26.

That increase rises my YOC to 4.05%

Click here to see my portfolio holdings.

You can follow the development of my dividends here.

Thanks for stopping by!

Recent Buy - Emera Incorporated (EMA.TO)

On Tuesday, October 25, I Bought 80 shares of  Emera Incorporated at CA$ 47.25 per share plus commission.

Emera Incorporated, an energy and services company, through its subsidiaries, engages in the generation, transmission, and distribution of electricity to various customers. The company is also involved in gas transmission and utility energy services businesses; and the provision of energy marketing, trading, and other energy-related management services. In addition, it transports re-gasified liquefied natural gas to consumers in the northeastern United States through its 145-kilometre pipeline in New Brunswick. The company serves approximately 506,000 customers in Nova Scotia; 158,000 customers in the state of Maine; and 126,000 customers in the island of Barbados. Emera Incorporated was founded in 1919 and is headquartered in Halifax, Canada.

Dividend Increase – AT&T Inc. (T)

On Saturday, October 22 AT&T Inc. announced a quarterly dividend increase of from $ 0.48 to $ 0.49 per share that’s payable February 1, 2017 to holders of record January 10, 2017. This represents a 2.08% increase to regular quarterly dividends. With current price $ 37.49 (Friday's close), this raise brings their dividend yield to 5.23%. 

Since I own 310 shares this will increase my yearly net dividends by $9.24.

That increase rises my YOC to 5.53%

Click here to see my portfolio holdings.

You can follow the development of my dividends here.

Thanks for stopping by!
 

Week in Review 42/16

Welcome and thanks for reading! In this review, I will gather together important and interesting news and events over the last week related to my portfolio holdings. In my week review, I put also together some interesting articles from other websites that caught my attention during the past week.

Week in Review 41/16

Welcome and thanks for reading! In this review, I will gather together important and interesting news and events over the last week related to my portfolio holdings. In my week review, I put also together some interesting articles from other websites that caught my attention during the past week.

Dividend Increase – Omega Healthcare Investors, Inc. (OHI)

Yesterday Omega Healthcare Investors, Inc. announced a quarterly dividend increase of from $0.60 to $0.61 per share that’s payable November 15, 2016 to holders of record October 31, 2016. This represents a 1.67% increase to regular quarterly dividends. With current price $32.95 (yesterday's close), this raise brings their dividend yield to 7.41%. 

Since I own 150 shares this will increase my yearly net dividends by $4.47.

That increase rises my YOC to 6.79%

Click here to see my portfolio holdings.

You can follow the development of my dividends here.

Thanks for stopping by!

Recent Buy - AbbVie Inc. (ABBV)

On Tuesday, October 11, I Bought 30 shares of  AbbVie Inc. at $ 62.98 per share plus commission.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis, including those with compensated cirrhosis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinsons disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; and Alvine Pharmaceuticals, Inc. The company is headquartered in North Chicago, Illinois and was spun off from Abbott Laboratories (ABT) in January 2013.

Week in Review 40/16

Welcome and thanks for reading! In this review, I will gather together important and interesting news and events over the last week related to my portfolio holdings. In my week review, I put also together some interesting articles from other websites that caught my attention during the past week.

Dividend Income - September 2016

Again, one month passed and it is time to report my dividend income. In June 2016 my portfolio dividend income was as follows:

Quarterly dividends received from: 

Intel Corporation (INTC) - €92.79 ($104.00)

Pfizer Inc. (PFE) - €53.57 ($60.00)

ConocoPhillips (COP) - €6.70 ($7.50)

Johnson & Johnson (JNJ) - €42.64 ($48.00) 
Archer Daniels Midland Co. (ADM) - €16.01 ($18.00)

Unilever N.V. (AMS:UNA) - €16.00 ($17.99)  

Emerson Electric Co. (EMR) - €16.91 ($19.00) 
Magna International Inc. (MGA) - €11.13 ($12.50)

Chevron Corporation (CVX) - €57.23 ($64.20) 

Target Corporation (TGT) - €53.48 ($60.00)
Flowers Foods Inc. (FLO) - €17.93 ($20.00)

McDonald's Corporation (MCD) - €15.95 ($17.80) 
Triton International Limited Co (TRTN) - €40.06 ($45.00)
Gilead Sciences Inc. (GILD) - €8.38 ($9.40) 

T. Rowe Price Group Inc. (TROW) - €26.46 ($29.70)
Digital Realty Trust Inc. (DLR) - €93.87 ($105.60)

Recent Buy - TD Bank Group (TD)

Yesterday on 4th October I added 25 shares of TD Bank Group (TD) at CA$ 58.30 per share plus commission (CA$ 5.00). My overall cost basis of this position increases from CA$ 53.76 to CA$ 54.42 per share. I totally hold now 180 shares of TD and my yield on cost is 4.04%. You can look at my first purchase of TD here.

Week in Review 39/16

Welcome and thanks for reading! In this review, I will gather together important and interesting news and events over the last week related to my portfolio holdings. In my week review, I put also together some interesting articles from other websites that caught my attention during the past week.